Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Abbisko Cayman Limited ( (HK:2256) ) has issued an update.
Abbisko Cayman Limited has announced the grant of 6,343,508 share options to three directors and certain employees under its Post-IPO Share Option Scheme. The options are subject to performance targets at both group and individual levels, with vesting scheduled over four years. This move aims to align the interests of the company’s leadership and employees with its strategic goals, potentially enhancing its competitive positioning in the pharmaceutical industry.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$22.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited is a company incorporated in the Cayman Islands with limited liability, listed on the Stock Exchange of Hong Kong. The company operates in the pharmaceutical industry, focusing on the development and commercialization of innovative drugs and therapies.
Average Trading Volume: 5,632,612
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.53B
Learn more about 2256 stock on TipRanks’ Stock Analysis page.